Chemotherapy drugs or toxic chemicals which are detoxified through hepatic glucuronidaiton can be reactivated by eG back to toxic form and thus inducing intestine damage, diarrhea, carcinogenesis, and colon cancer. Therefore, we have successfully developed eG specific inhibitor as a novel drug for chemo-induced damage and colorectal cancer.

Glucuronidation is a major process for toxin detoxification occurring mainly in the liver. Generally, carcinogens or drugs are conjugated with glucuronic acid to be inactive and facilitate their subsequent elimination from the body. However, when the pharmacologically inactive glucuronides enter the intestine via bile through enterohepatic circulation, they are reactivated by bacterial -glucuronidase (G), releasing the cytotoxic drugs and thus leading to intestinal injury. Repeatedly direct exposure of epithelium to carcinogens in the intestine leads to gene mutation and cell damage that increases the risk for colorectal malignancies. Therefore, we developed bacterial G-specific inhibitor as a novel drug for the following use: 
3.Chemoprevention drug or treatment drug: For the patients with high risk of developing colorectal cancer, the inhibitor can be used to prevent reactivating of the carcinogen in the intestine and thus reducing chemo-induced carcinogenesis and colon cancer.
Chemotherapy adjuvant: The inhibitor can be combined with chemo drug to prevent chemotherapy -induced intestinal damage and diarrhea, thus improving patients’ quality of life and increasing patient’s drug tolerance to increase therapy efficacy.

本腸道菌eG專一性抑制劑可阻止肝解毒之藥物或致癌劑於腸道再度活化，造成腸道刺激、損傷最後形成大腸癌。並可應用於:
(1)化療藥口服佐劑，預防化療腸道破壞並改善療效
防止化療藥物於腸道再度活化，造成腸道破壞、腹瀉或血便的副作用。防止病人因嚴重之副作用導致停藥的情形，使病人可以完成治療療程，達到最好的治療效果。
(2)預防大腸癌創新藥物
防止致癌劑於腸道回復毒性，造成腸道病變與大腸癌。預防大腸癌發生，是以預防醫學為主要市場。